143707-72-6

Basic information

• Product Name: H-BETA-MEALA-OTBU
• Synonyms: N-METHYL-BETA-ALANINE ALPHA-T-BUTYL ESTER;H-BETA-MEALA-OTBU;TERT-BUTYL 3-(METHYLAMINO)PROPIONATE;tert-butyl 3-(methylamino)propanoate
• CAS NO: 143707-72-6
• Molecular Formula: C₈H₁₇NO₂
• Molecular Weight: 159.23
• Mol File: 143707-72-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 203.7±23.0 °C(Predicted)
• Appearance: /
• Density: 0.920±0.06 g/cm3(Predicted)
• PKA: 9.47±0.10(Predicted)
• CAS DataBase Reference: H-BETA-MEALA-OTBU(CAS DataBase Reference)
• NIST Chemistry Reference: H-BETA-MEALA-OTBU(143707-72-6)
• EPA Substance Registry System: H-BETA-MEALA-OTBU(143707-72-6)

Safety Data

• Hazardous Substances Data: 143707-72-6(Hazardous Substances Data)

Usage

General Description

H-BETA-MEALA-OTBU is a chemical compound that belongs to the class of beta-amino acids and is commonly used in organic synthesis. It is a derivative of beta-alanine, which is a non-essential amino acid that acts as a neurotransmitter and is involved in the metabolism of sugar and fat. H-BETA-MEALA-OTBU has been studied for its potential use as a building block in the synthesis of pharmaceuticals and biologically active compounds. It is known for its ability to form stable derivatives and can readily react with other chemicals to form new compounds. As a result, it has been of interest to researchers in the field of medicinal chemistry and drug development.

Upstream product

• 1663-39-4 tert-Butyl acrylate 
• 593-51-1 methylamine hydrochloride 
• 74-89-5 methylamine 
• 124072-61-3 N-t-butoxycarbonyl-N-methyl-β-alanine 
• 634916-43-1 N-benzyl-N-methyl-β-alanine tert-butyl ester 
• 654651-69-1 Boc-MeβAla-OtBu 

Downstream Products

• 634915-81-4 N-Boc-L-Phe-N-Me-β-Ala-O-t-Bu 
• 1169930-14-6 tert-butyl 3-((3-(3-(hydroxymethyl)-phenoxy)propyl)(methyl)amino)propanoate 
• 1346134-46-0 methyl 4-{2-[4-({[2-({3-[(3-tert-butoxy-3-oxopropyl)(methyl)sulfamoyl]benzoyl}amino)-4,5,6,7-tetrahydro-1-benzothiophen-3-yl]carbonyl}amino)phenyl]ethyl}benzoate 
• 1141474-44-3 tert-butyl 3-[{3-[amino(hydroxyimino)methyl]benzyl}(methyl)amino]propanoate 
• 1141474-45-4 tert-butyl 3-[(3-cyanobenzyl)(methyl)amino]propanoate 
• 1246527-03-6 tert-butyl N-{4-[amino(hydroxyimino)methyl]benzyl}-N-methyl-β-alaninate 
• 1246527-02-5 tert-butyl N-(4-cyanobenzyl)-N-methyl-beta-alaninate 
• 1307813-94-0 C₃₀H₃₀F₃N₃O₄ 
• 1211325-12-0 C₄₆H₅₀F₄N₃O₄⁽¹⁺⁾*Cl^(1-) 
• 1141474-47-6 tert-butyl N-(5-cyano-2-fluorobenzyl)-N-methyl-beta-alaninate 
• 886236-39-1 tert-butyl 3-[(2,3-dichlorobenzenesulphonyl)methylamino]propionate 
• 654652-06-9 Boc-Tyr(CO-1-adamantyl)-D-MetO-Phe-MeβAla-OtBu 
• 654652-04-7 Boc-Tyr(CO-n-heptyl)-D-MetO-Phe-MeβAla-OtBu 
• 654652-08-1 Boc-Tyr(COCH2CH2CH2Ph)-D-MetO-Phe-MeβAla-OtBu 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER

The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for (use in) the treatment and/or prophylaxis of liver cancer.

7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION

The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds as TLR7 agonists for the treatment of viral infections.